Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Next-Generation Sequencing (NGS) Market.
Trusted Business Insights presents an updated and Latest Study on Next-Generation Sequencing (NGS) Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Next-Generation Sequencing (NGS) Market during the forecast period.
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.
Get Sample Copy of this Report @ Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2020 – 2029 (Includes COVID-19 Business Impact)
We have updated Next-Generation Sequencing (NGS) Market with respect to COVID-19 Business Impact.
Inquire before buying
This report focuses on the Next-Generation Sequencing (NGS) market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Next-Generation Sequencing (NGS) market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.
Global Next-Generation Sequencing (NGS) Market: Segment Analysis
The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.
Global Next-Generation Sequencing (NGS) Market: Regional Analysis
The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.
Global Next-Generation Sequencing (NGS) Market: Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
Next-Generation Sequencing (NGS) Market Players
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- PerkinElmer Inc.
- Eurofins Scientific
- Macrogen, Inc.
- Other prominent players
Sequencing of DNA fragments have helped in the diagnosis of diseases, research, drug discovery, forensics, and others. Next-generation sequencing, also called as high through-put sequencing is a useful platform that enables the sequencing of millions of DNA molecules simultaneously. The demand for next-generation sequencer is booming drastically, owing to its advantage of sequencing millions of DNA fragments in a single run. Many of the upcoming genetic tests such as Non-invasive Prenatal Testing (NIPT), Preimplantation Genetic Testing (PGT), virology, molecular testing, cancer diagnosis, and others are based on this technology. The increasing clinical application of NGS, increasing research, initiation of genome projects in various countries, adoption of personalized medicines, and advancements in bioinformatics are expected to further boost the market.
The next-generation sequencing market report provides qualitative and quantitative insights on the industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market segments include type, application, end user, and region. Based on type, this market is segmented into products and services. The products segment is further bifurcated into instruments & software and consumables. In terms of application, the market is divided into diagnostics, research, and others. Various end users covered under the report are research institutes, healthcare facilities & diagnostic centers, pharmaceutical & biotechnological companies, Contract Research Organization (CROs). Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.
Along with this, the NGS market report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the overview of diagnostic tests, new product launch, regulatory scenario for key countries, startups with their funding overview, recent industry developments such as mergers & acquisitions, and key industry trends.
- Instruments & Software
By End User
- Research Institutes
- Healthcare Facilities & Diagnostic Centers
- Pharmaceutical & Biotechnological Companies
- Contract Research Organization (CROs)
- North America (the USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)
Key Industry Developments
In June 2019, Saphetor announced its partnership with Swift Biosciences Inc. aiming to accelerate and standardize data interpretation solution for targeted next-generation sequencing panels.
In January 2019, PierianDx announced partnership with Illumina to provide the customers with informatics services for Illuminas oncology products further supporting cancer diagnostics and research.
In November 2017, Illumina, announced the launch of NextSeq 550Dx instrument, the companys second FDA and CE marked NGS platform to diversify its diagnostic product portfolio.
In September 2018, the FDA granted marketing approval to ClonoSEQ assay, a next-generation sequencing-based diagnostic test developed by Adaptive Biotechnologies Corp. for minimal residual disease (MRD), in patients having acute lymphoblastic leukemia (ALL) or multiple myeloma
In June 2018, Agilent Technologies announced the launch of Agilent OnePGT, a NGS solution for Preimplantation Genetic Testing (PGT).
Quick Read Table of Contents of this Report @ Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2020 – 2029 (Includes COVID-19 Business Impact)
Trusted Business Insights
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580